Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial - PubMed

Affiliations

• PMID: 10390007
• PMCID: PMC2363002
• DOI: 10.1038/sj.bjc.6690350

Free PMC article

Clinical Trial

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

J S Waters et al. Br J Cancer. 1999 Apr.

Free PMC article

Abstract

We report the final results of a prospectively randomized study that compared the combination of epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with the standard combination of 5-FU, doxorubicin and methotrexate (FAMTX) in previously untreated patients with advanced oesophagogastric cancer. Between 1992 and 1995, 274 patients with adenocarcinoma or undifferentiated carcinoma were randomized from eight oncology centres in the UK and analysed for response and survival. The overall response rate was 46% (95% confidence interval (CI), 37-55%) with ECF, and 21% (95% CI, 13-28%) with FAMTX (P = 0.00003). The median survival was 8.7 months with ECF and 6.1 months with FAMTX (P = 0.0005). The 2-year survival rates were 14% (95% CI, 8-20%) for the ECF arm, and 5% (95% CI, 2-10%) for the FAMTX arm (P = 0.03). Histologically complete surgical resection following chemotherapy was achieved in ten patients in the ECF arm (three pathological complete responses to chemotherapy) and three patients in the FAMTX arm (no pathological complete responses). The ECF regimen resulted in a response and survival advantage compared with FAMTX chemotherapy. The probability of long-term survival following surgical resection of residual disease is increased by this treatment. The high response rates seen with ECF support its use in the neoadjuvant setting.

Similar articles

• Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

  Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Webb A, et al. J Clin Oncol. 1997 Jan;15(1):261-7. doi: 10.1200/JCO.1997.15.1.261. J Clin Oncol. 1997. PMID: 8996151 Clinical Trial.

• Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.

  Bamias A, Hill ME, Cunningham D, Norman AR, Ahmed FY, Webb A, Watson M, Hill AS, Nicolson MC, O'Brien ME, Evans TC, Nicolson V. Bamias A, et al. Cancer. 1996 May 15;77(10):1978-85. doi: 10.1002/(SICI)1097-0142(19960515)77:10<1978::AID-CNCR3>3.0.CO;2-D. Cancer. 1996. PMID: 8640659 Clinical Trial.

• Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.

  Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dörken B, Reichardt P. Thuss-Patience PC, et al. J Clin Oncol. 2005 Jan 20;23(3):494-501. doi: 10.1200/JCO.2005.02.163. J Clin Oncol. 2005. PMID: 15659494 Clinical Trial.

• [Recent advances in chemotherapy for advanced gastric cancer: from the standpoint of survival advantages].

  Ohtsu A, Yoshida S, Miyata Y, Shimada Y. Ohtsu A, et al. Gan To Kagaku Ryoho. 1995 Mar;22(4):444-50. Gan To Kagaku Ryoho. 1995. PMID: 7887636 Review. Japanese.

• The treatment of advanced gastric cancer.

  Wils J. Wils J. Semin Oncol. 1996 Jun;23(3):397-406. Semin Oncol. 1996. PMID: 8658224 Review.

Cited by

• Antibiotics: Conventional Therapy and Natural Compounds with Antibacterial Activity-A Pharmaco-Toxicological Screening.

  Pancu DF, Scurtu A, Macasoi IG, Marti D, Mioc M, Soica C, Coricovac D, Horhat D, Poenaru M, Dehelean C. Pancu DF, et al. Antibiotics (Basel). 2021 Apr 7;10(4):401. doi: 10.3390/antibiotics10040401. Antibiotics (Basel). 2021. PMID: 33917092 Free PMC article. Review.

• Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.

  Duo-Ji MM, Ci-Ren BS, Long ZW, Zhang XH, Luo DL. Duo-Ji MM, et al. Oncotarget. 2017 Jun 6;8(23):37896-37911. doi: 10.18632/oncotarget.14664. Oncotarget. 2017. PMID: 28099947 Free PMC article.

• Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.

  Chau I, Penel N, Soriano AO, Arkenau HT, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Bendell JC, Mi G, Gao L, McNeely SC, Oliveira JM, Ferry D, Herbst RS, Fuchs CS. Chau I, et al. Cancers (Basel). 2020 Oct 15;12(10):2985. doi: 10.3390/cancers12102985. Cancers (Basel). 2020. PMID: 33076423 Free PMC article.

• A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.

  Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C. Kollmannsberger C, et al. Br J Cancer. 2000 Aug;83(4):458-62. doi: 10.1054/bjoc.2000.1295. Br J Cancer. 2000. PMID: 10945491 Free PMC article. Clinical Trial.

• Recent advances in the treatment of gastric cancer.

  Sun W, Haller DG. Sun W, et al. Drugs. 2001;61(11):1545-51. doi: 10.2165/00003495-200161110-00002. Drugs. 2001. PMID: 11577792 Review.

References

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Medical

  • MedlinePlus Health Information